ABBOTINDIAAbbott India Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, pain management, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on ABBOTINDIA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • ROE: 34.5%
- • ROCE: 36.7%
- • Debt/Equity: 0.04
- • Volatility: 20% annualized
- • Max drawdown (1y): 17%
- • Liquidity: ₹14.8 cr avg turnover
Bull case
- • ROE: 34.5%
- • ROCE: 36.7%
- • Debt/Equity: 0.04
- • Volatility: 20% annualized
Bear case
- • Revenue growth: 6.5% YoY
- • Profit growth: 7.6% YoY
- • RSI: 38
- • MACD: bearish
Key risks
- • Momentum is fading versus the broader market
- • Revenue growth: 6.5% YoY
- • Profit growth: 7.6% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹571.41). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.